#37: MCET News MultiCell Technologies Announces Strategic Initiatives for 2006 and 2007; Company to Focus on Advance of First-in-Class Immune-based Drug Candidates into Advanced Phase Human Clinical Trials
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. [OTCBB:MCET],
developing first-in-class drugs based on advanced immune system
modulation and other proprietary technologies,...
#36: MCET News SmallCapInsights.com Investment Newsletter Commences Editorial Coverage of MultiCell Technologies Following Recently Filed Patent on Cancer Treatment
SAN DIEGO--(BUSINESS WIRE)--SmallCapInsights.com, a leading investment newsletter committed to
discovering tomorrow's smallcap breakthroughs, has announced the online
release of a new...
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. [OTCBB: MCET],
developing first-in-class drugs based on advanced immune system
modulation and other proprietary technologies,...
LINCOLN, R.I.--(BUSINESS WIRE)--July 28, 2006--MultiCell Technologies Inc. (OTCBB:MCET), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and...
LINCOLN, R.I.--(BUSINESS WIRE)--July 20, 2006--MultiCell Technologies Inc. (OTCBB:MCET), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and...
LINCOLN, R.I. & LONDON--(BUSINESS WIRE)--Jan. 3, 2006--MultiCell Technologies, Inc. (OTCBB: MCET) and Amarin Corporation plc (NasdaqSC: AMRN) announced today that MultiCell has exclusively licensed...
LINCOLN, R.I.--(BUSINESS WIRE)--Dec. 1, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that it has entered into a research agreement to investigate a novel anti-apoptosis...
LINCOLN, R.I.--(BUSINESS WIRE)--Nov. 30, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced that AstraZeneca (NYSE:AZN) scientists presented a paper at the American Association of...
LINCOLN, R.I.--(BUSINESS WIRE)--Nov. 9, 2005--MultiCell Technologies, Inc. (OTCBB:MCET) announced that its subsidiary, MultiCell ImmunoTherapeutics, has elevated MCT-465 to lead drug candidate...
LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 28, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that XenoTech LLC, MultiCell's marketing and manufacturing licensee, introduced an improved...
#27: MCET News MultiCell Immunotherapeutics Data Demonstrates Potential to Prevent Avian Flu; Pre-Clinical Mouse Models Show 1,000-fold Reduction in Viral Load in H1N1 Strain
LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 21, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that pre-clinical tests conducted by scientists at MultiCell's San Diego laboratories...
LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 20, 2005--MultiCell Technologies, Inc. (OTCBB: MCET), announced today that the Company has entered into a research collaboration with Thomas Jefferson...
#25: MCET News MultiCell Enters into a Joint Venture with Living Cell Technologies to Develop Adult Liver Cell Technologies for Drug Discovery, Protein Production and Therapeutic Clinical Applications
LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 4, 2005--MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug...
LINCOLN, R.I.--(BUSINESS WIRE)--Sept. 26, 2005--MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug...
#23: MCET News MultiCell Technologies Appoints Anthony Altig to Board; Experienced Biotechnology Executive to Help Company Develop Therapeutic Platform
LINCOLN, R.I.--(BUSINESS WIRE)--Sept. 19, 2005--MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug...
